KR970705995A - Scopolamine patch - Google Patents

Scopolamine patch

Info

Publication number
KR970705995A
KR970705995A KR1019970701700A KR19970701700A KR970705995A KR 970705995 A KR970705995 A KR 970705995A KR 1019970701700 A KR1019970701700 A KR 1019970701700A KR 19970701700 A KR19970701700 A KR 19970701700A KR 970705995 A KR970705995 A KR 970705995A
Authority
KR
South Korea
Prior art keywords
treatment system
patch
membrane
transdermal therapeutic
saturation solubility
Prior art date
Application number
KR1019970701700A
Other languages
Korean (ko)
Other versions
KR100394830B1 (en
Inventor
뮐러 발터
Original Assignee
프랭크 베허, 베르너 베슬링
엘테에스 로만 테라피-지스템 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프랭크 베허, 베르너 베슬링, 엘테에스 로만 테라피-지스템 게엠베하 filed Critical 프랭크 베허, 베르너 베슬링
Publication of KR970705995A publication Critical patent/KR970705995A/en
Application granted granted Critical
Publication of KR100394830B1 publication Critical patent/KR100394830B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 패치 형태의 스코폴아민 함유 트랜스더멀 치료 시스템은 활성물질 함유층이 전체 비히클 제제 중에서 포화 용해도가 50~100%, 바람직하게는 60~100%에 상당하는 농도로 아크릴산 또는 메타아크릴산 유도체의 공중합체 및 스코폴아민 기제를 기제 중합체로서 함유하는 것을 특징으로 한다.The present invention relates to a scaffold amine containing transdermal therapeutic system in the form of a patch, wherein the active substance-containing layer has a saturation solubility in the total vehicle formulation of from 50 to 100%, preferably from 60 to 100%, of an aerosol of acrylic acid or methacrylic acid derivative And a skeletal amine group as a base polymer.

Description

스코폴아민 패치Scopolamine patch

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (8)

백킹층, 감압성 접착성 화성물질 저장기, 경우에 따라 활성물질 유량을 조절하는 막, 임의로 추가 피부 접촉층 및 제거가능한 보호막으로 된 층상 구조를 갖고 활성물질 스코아폴아민 기재를 함유하는 패치 형태의 트랜스더멀 치료 시스템에 있어서, 상기 패치의 활성물질 함유 층은 전체 비히클 제제 중에서 포화 용해도가 50~100%, 바람직하게는 60~100%에 상당하는 농도로 아크릴산 또는 메타크릴산 유도체의 공중합체 및 스코폴아민 기제를 기제 중합체로서 함유하는 것을 특징으로 하는 트랜스더멀 치료 시스템.A backing layer, a pressure-sensitive adhesive material reservoir, a membrane that optionally regulates the flow rate of the active material, optionally a further skin contact layer, and a removable protective film, and is in the form of a patch containing the active substance scopolamine substrate In the transdermal therapeutic system, the active substance-containing layer of the patch is a copolymer of acrylic acid or methacrylic acid derivative and a copolymer of acrylic acid or methacrylic acid derivative in a concentration corresponding to a saturation solubility of 50 to 100%, preferably 60 to 100% A transdermal therapeutic system comprising a polyamine base as a base polymer. 제1항에 있어서, 상기 트랜스더멀 치료 시스템은 매트릭스 시스템인 것을 특징으로 하는 트랜스더멀 치료 시스템.2. The transducer treatment system of claim 1, wherein the transducer treatment system is a matrix system. 제1항에 있어서, 상기 트랜스더멀 치료 시스템은 막 시스템인 것을 특징으로 트랜스더멀 치료 시스템.2. The transducer treatment system of claim 1, wherein the transducer treatment system is a membrane system. 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 막은 에틸렌과 비닐 아세테이트의 공중합체로 이루어진것을 특징으로 하는 트랜스더멀 치료 시스템.4. The transdermal therapeutic system according to any one of claims 1 to 3, wherein the membrane is made of a copolymer of ethylene and vinyl acetate. 제4항에 있어서, 상기 막은 비닐 아세테이트 함량이 4% 이상인 것을 특징으로 하는 트랜스더멀 치료 시스템.5. The transducer treatment system of claim 4, wherein the membrane has a vinyl acetate content of at least 4%. 제1항 내지 제5항 중 어느 한 항에 있어서, 접착제 또는 접착제/보조제 혼합물 중의 스코폴아민 기제의 포화 용해도는 10~30중량%인 것을 특징으로 하는 트랜스더멀 치료 시스템.6. Transdermal therapeutic system according to any one of claims 1 to 5, characterized in that the saturation solubility of the scopolamine base in the adhesive or adhesive / adjuvant mixture is 10 to 30% by weight. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 패치의 활성물질 함유층은 스코폴아민 기제의 포화 용해도를 감소시키기 위해 탄산수소, 바람직하게는 디옥틸 사이클로헥산으로 구성되는 것을 특징으로 하는 트랜스더멀 치료 시스템.7. A process according to any one of claims 1 to 6, characterized in that the active substance-containing layer of the patch is composed of hydrogencarbonate, preferably dioctylcyclohexane, in order to reduce the saturation solubility of the scopolamine base. Dermal treatment system. 제1항 내지 제7항 중 어느 한 항에 있어서, 상기 패치의 활성불질 함유층은 포화 용해도, 바람직하게는 올레산 및 올레일 알콜을 증가시키 위해 지방산 또는 지방족 알콜로 구성되는 것을 특징으로 하는 트랜스더멀 치료 시스템.8. A process according to any one of claims 1 to 7, wherein the active oxygen-containing layer of the patch is composed of fatty acids or aliphatic alcohols to increase the saturation solubility, preferably oleic acid and oleyl alcohol. system. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701700A 1994-09-16 1995-09-09 Scopolamine patch KR100394830B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4433004 1994-09-16
DEP4433004.9 1994-09-16
DE4438989A DE4438989C2 (en) 1994-09-16 1994-10-31 Scopolamine patches
DEP4438989.2 1994-10-31

Publications (2)

Publication Number Publication Date
KR970705995A true KR970705995A (en) 1997-11-03
KR100394830B1 KR100394830B1 (en) 2004-02-14

Family

ID=6528376

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701700A KR100394830B1 (en) 1994-09-16 1995-09-09 Scopolamine patch

Country Status (3)

Country Link
KR (1) KR100394830B1 (en)
DE (1) DE4438989C2 (en)
ZA (1) ZA957812B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19738643C2 (en) 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermal therapeutic system with the active ingredient scopolamine base and process for its preparation
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD279611A1 (en) * 1985-03-07 1990-06-13 Univ Ernst Moritz Arndt METHOD FOR PRODUCING A RESISTANT FILM
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
DD279818A1 (en) * 1989-02-06 1990-06-20 Jenapharm Veb METHOD FOR PRODUCING A MEDICAL PLASTER
DE3908431A1 (en) * 1989-03-15 1990-09-27 Lohmann Therapie Syst Lts TRANSDERMAL SYSTEM WITH STAGE SUBSTANCE DELIVERY AND USE FOR LOCAL OR SYSTEMIC DISPENSER

Also Published As

Publication number Publication date
DE4438989A1 (en) 1996-03-21
DE4438989C2 (en) 1999-02-25
ZA957812B (en) 1996-05-13
KR100394830B1 (en) 2004-02-14

Similar Documents

Publication Publication Date Title
US5238933A (en) Skin permeation enhancer compositions
US5122383A (en) Sorbitan esters as skin permeation enhancers
US5229130A (en) Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5985317A (en) Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CA2098196C (en) Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers
CA2459483C (en) Plaster for the treatment of dysfunctions and disorders of nail growth
US5700480A (en) Transdermal therapeutic system comprising galanthamine as active component
US5227169A (en) Sorbitan esters as skin permeation enhancers
AU678237B2 (en) Active substance-containing plaster
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
AU651234B2 (en) Transdermal estradiol delivery system
KR101000945B1 (en) Matrix-type transdermal drug delivery system and preparation method thereof
EP0227816A1 (en) Transdermal verapamil delivery device
KR900009084A (en) Topical and transdermal administration systems containing 1-isobutyl-1H-imidazo [4,5-c] quinolin-4-amine
US5212199A (en) Sorbitan esters as skin permeation enhancers
JP4430120B2 (en) Antimycotic patch
KR100248365B1 (en) Penetration-promoting substance
AU2108300A (en) Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids
US5385736A (en) Transdermal melatonin delivery system
KR970705995A (en) Scopolamine patch
WO2002009653A1 (en) Adhesive cosmetic patches
PT1011674E (en) TRANSDERMIC THERAPEUTIC SYSTEM WITH THE ACTIVE SUBSTANCE SCOPOLAMINE BASE
US5972376A (en) Transdermal system of tacrine/selegilin-plaster
KR950703948A (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING PHYSOSTIGMIN THROUGH THE SKIN <AND A METHOD OF PRODUCING THE SYSTEM
JPH02149514A (en) Material for medicine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120723

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20130726

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee